Abstract 1366P
Background
Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) inhibitor, has been the standard of care for untreated and previously treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The common adverse events (AEs) of lorlatinib leading to drug discontinuation or dose reduction were hyperlipidemia, edema, and central nervous system (CNS)/ psychiatric disorders. The association between AEs and serum concentrations of lorlatinib remains unclear.
Methods
We retrospectively reviewed advanced ALK-positive NSCLC patients treated with lorlatinib between December 2018 and July 2022. The association between AEs and serum concentrations of lorlatinib was assessed at 28 days (± 14 days) after the initiation of lorlatinib using a high-performance liquid chromatography tandem mass spectrometry.
Results
Among 55 eligible patients, the median age was 54 years (range: 23–79) and the median number of treatment lines was 2 (range: 2-10). Most patients were female (29 [53%]) and performance status 0-1 (48 [87%]). Grade 3 or higher AEs occurred in 23 patients (42%) including hyperlipidemia in 18 (33%), edema in 5 (9%), and CNS/ psychiatric disorders in 4 (7%). Discontinuation or dose reduction was required in 21 patients (38%). Serum concentrations were measured in 36 patients (65%) and were significantly higher in the patients experiencing grade 3 or higher AEs than those without (462 ng/mL vs 177 ng/mL, p<0.01). On the other hand, there was no significant difference in progression-free survival (PFS) between the patients who had experienced the discontinuation or dose reduction within the first 6 months and those who had not (12.8M vs 5.2M, p=0.14).
Conclusions
The incidence of grade 3 or higher AEs with lorlatinib was associated with high serum concentrations at the first month of treatment. Drug discontinuation or dose reduction had no impact on PFS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Yoshida: Financial Interests, Personal and Institutional, Research Grant, Personal fees: Amgen, AstraZeneca, Ono, MSD, Novartis, Chugai, BMS; Financial Interests, Institutional, Research Grant: Takeda, Daiichi Sankyo, AbbVie; Financial Interests, Personal, Speaker’s Bureau, Personal fees: Taiho, Lilly, Roche, ArcherDX. Y. Matsumoto: Financial Interests, Institutional, Research Grant: National Cancer Center Research and Development Fund, Grant-in-Aid for Scientific Research on Innovative Areas, Hitachi, Ltd; Financial Interests, Personal and Institutional, Research Grant, Personal fees: Olympus; Financial Interests, Personal, Speaker’s Bureau, Personal fees: AstraZeneca, Novartis, Cook, Amco Inc, Thermo Fisher Scientific, Erbe Elektromedizin GmbH, Fujifilm, Chugai, Eli Lilly. Y. Shinno: Financial Interests, Personal, Speaker’s Bureau, Personal fees: BMS, Chugai, AstraZeneca, Eli Lilly; Financial Interests, Personal and Institutional, Research Grant, Personal fees: Ono; Financial Interests, Institutional, Research Grant: Janssen, Japan Clinical Research Operations K.K. Y. Okuma: Financial Interests, Institutional, Research Grant: Roche, AbbVie K.K; Financial Interests, Personal, Speaker’s Bureau, Personal fees: AstraZeneca, EIi Lilly K.K, Bristol Myers Squibb, Pfizer, Taiho Pharma Co. Ltd., AstraZeneca, Nippon, Boehringer Ingelheim, Chugai Pharma Co. Ltd., Ono Pharma Co. Ltd., Taiho Pharma Co. Ltd.. Y. Goto: Financial Interests, Institutional, Research Grant: AZK, AbbVie, Kyorin, Preferred Network; Financial Interests, Personal and Institutional, Research Grant, Personal fees: Pfizer, Eli Lilly, Bristol Myers Squibb, Ono, Novartis, Daiichi Sankyo; Financial Interests, Personal, Speaker’s Bureau, Personal fees: Chugai, Taiho, Boehringer Ingelheim, MSD, Merck, Thermo Fischer, AstraZeneca, Chugai, Guardant Health Inc., Illumina. H. Horinouchi: Financial Interests, Personal and Institutional, Research Grant, Personal fees: MSD, AstraZeneca, BMS, Ono, Chugai, Roche, Novartis; Financial Interests, Institutional, Research Grant: AbbVie, Merck Biophama, Daiichi Sankyo, Janssen, Genomic Health; Financial Interests, Personal, Speaker’s Bureau, Personal fees: Eli Lilly, Kyowa-Kirin. N. Yamamoto: Financial Interests, Personal and Institutional, Research Grant, Personal fees: Chugai, Eisai, Lilly, BMS, Pfizer, Boehringer Ingelheim, Ono Pharmaceutical Co., Ltd, Takeda, Otsuka; Financial Interests, Institutional, Research Grant: Taiho, Quintiles, Astellas, Novartis, Daiichi Sankyo, Kyowa-Hakko Kirin, Bayer, Janssen Pharma, MSD, Merck, GSK, Sumitomo Dainippon, Chiome Bioscience Inc., Carna Biosciences, Genmab, Shionogi; Financial Interests, Personal, Speaker’s Bureau, Personal fees: Sysmex, AstraZeneca, Cimic. Y. Ohe: Financial Interests, Personal and Institutional, Research Grant, Personal fees: AstraZeneca, Chugai, Eli Lilly, Ono, BMS, Kyorin, Pfizer, Taiho; Financial Interests, Institutional, Research Grant: Dainippon-Sumitomo, Novartis, Takeda, Kissei, Daiichi Sankyo, Janssen, Loxo; Financial Interests, Personal, Speaker’s Bureau, Personal fees: Boehringer Ingelheim, Bayer, MSD, Nippon Kayaku, Kyowa Hakko Kirin, Celltrion, Amgen, An Heart Tharapeutics Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1078TiP - Phase I/II, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 (anti-VISTA) as monotherapy and in combination with cemiplimab in patients (pts) with advanced solid tumors
Presenter: Kyriakos Papadopoulos
Session: Poster session 19
1079TiP - A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies
Presenter: Shiraj Sen
Session: Poster session 19
1080TiP - An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)
Presenter: Vladimir Galvao
Session: Poster session 19
1325P - Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
Presenter: James Chih-Hsin Yang
Session: Poster session 19
1326P - Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
Presenter: David Planchard
Session: Poster session 19
1327P - First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)
Presenter: Daniel Breadner
Session: Poster session 19
1328P - Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib
Presenter: Meredith LaRose
Session: Poster session 19
1329P - FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
Presenter: Lucia Nogova
Session: Poster session 19
1330P - Updated results of the efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EGFR-TKI(s)
Presenter: Caicun Zhou
Session: Poster session 19